Related Experiment Videos

[Anticancer drug screening test for human osteosarcoma transplanted into nude mice]

K Mochizuki1

  • 1Department of Orthopaedic Surgery, Kyorin University School of Medicine, Tokyo, Japan.

Nihon Seikeigeka Gakkai Zasshi
|November 1, 1988
PubMed

Insights

A novel toluidine-blue staining method effectively screens anticancer drug efficacy in osteosarcoma models. Cis-platinum demonstrated the highest effectiveness among tested drugs, validating the new method.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Context:

  • Osteosarcoma is a challenging bone cancer requiring effective therapeutic strategies.
  • Preclinical models are crucial for evaluating novel anticancer agents.
  • Traditional methods for assessing drug efficacy can be time-consuming.

Purpose:

  • To evaluate the efficacy of five anticancer drugs against osteosarcoma xenografts in nude mice.
  • To introduce and validate a novel toluidine-blue staining method for assessing drug-induced tumor cell viability.
  • To compare the efficacy of Cis-platinum, SF-1739HP, Melphalan, Peleomycin, and Aclacinomycin.

Summary:

  • Osteosarcoma tissue was xenografted into nude mice, and various anticancer drugs were administered.
  • Tumor growth was monitored, and a new method involving toluidine-blue staining of tumor cell suspensions was developed.
  • The staining method classified tumor cells into strongly-positive, weakly-positive, and negative categories, correlating well with traditional tumor weight measurements.
  • Cis-platinum exhibited the most significant anticancer effect, followed by SF-1739HP, Melphalan, Peleomycin, and Aclacinomycin.

Impact:

  • The toluidine-blue staining method provides a simple and efficient approach for screening anticancer drug effectiveness.
  • This method can accelerate the discovery and development of new osteosarcoma treatments.
  • Findings confirm Cis-platinum's potent activity and rank other agents, aiding future therapeutic decisions.

Related Concept Videos